Targets › IGF1
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Dec 2027.
The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. (UniProt, P05019)
Open in Phaseline: the race on IGF1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biohaven Pharmaceuticals | taldefgrobep alfa Engineered IGF-1 analog; recombinant human IGF-1 receptor agonist | IGF1 | Phase 3 | Spinal Muscular Atrophy | Dec 2027 |
Spinal Muscular Atrophy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.